Literature DB >> 17785502

Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans.

Marietta Anderwald-Stadler1, Michael Krebs, Miriam Promintzer, Martina Mandl, Martin G Bischof, Peter Nowotny, Thomas Kästenbauer, Anton Luger, Rudolf Prager, Christian Anderwald.   

Abstract

Obestatin, a recently discovered 23-amino acid peptide, is involved in the regulation of appetite and body weight in antagonistic fashion to ghrelin, both deriving from a common precursor peptide. Ghrelin was shown to be associated with insulin resistance, which may also affect obestatin. We investigated the association between insulin resistance and plasma concentrations of obestatin and ghrelin in nondiabetic individuals with high (IS; n = 18, 13 females and 5 males, age 47 +/- 2 yr, BMI = 25.5 +/- 0.9 kg/m(2)) and low (IR; n = 18, 12 females and 6 males, age 45 +/- 2 yr, P = 0.49, BMI = 27.5 +/- 1.1 kg/m(2), P = 0.17) insulin-stimulated glucose disposal (M), measured by 2-h hyperinsulinemic (40 mU.min(-1).m(-2)) isoglycemic clamp tests. M(100-120 min) was higher in IS (10.7 +/- 0.7) than in IR (4.4 +/- 0.2 mg.min(-1).kg(-1), P < 10(-9)), whereas insulin-dependent suppression of free fatty acids (FFA) in plasma was reduced in IR (71 +/- 6% vs. IS: 82 +/- 5%, P < 0.02). In both groups, plasma ghrelin concentrations were comparable at fasting and similarly reduced by 24-28% during insulin infusion. IR had lower fasting plasma obestatin levels (383 +/- 26 pg/ml vs. IS: 469 +/- 23 pg/ml, P < 0.02). Clamp insulin infusion reduced plasma obestatin to approximately 81% of basal values in IS (P < 0.00002), but not in IR. Fasting plasma obestatin was correlated positively with M (r = 0.34, P = 0.04), HDL cholesterol (r = 0.45, P = 0.01), and plasma ghrelin concentrations (r = 0.80, P < 0.000001) and negatively with measures of adiposity, plasma FFA during clamp (r = -0.42, P < 0.01), and systolic blood pressure (r = -0.33, P < 0.05). In conclusion, fasting plasma concentrations of obestatin, but not of ghrelin, are reduced in insulin resistance and are positively associated with whole body insulin sensitivity in nondiabetic humans. Furthermore, plasma obestatin is reduced by insulin in insulin-sensitive but not in insulin-resistant persons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785502     DOI: 10.1152/ajpendo.00330.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  16 in total

1.  Circulating obestatin levels in normal and Type 2 diabetic subjects.

Authors:  D H St-Pierre; F Settanni; I Olivetti; E Gramaglia; M Tomelini; R Granata; F Prodam; A Benso; E Ghigo; F Broglio
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

2.  The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling.

Authors:  Andrew J Agnew; Emma Robinson; Carmel M McVicar; Adam P Harvey; Imran H A Ali; Jennifer E Lindsay; Denise M McDonald; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD).

Authors:  Aybike Birerdinc; Sasha Stoddard; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2018-04-19

Review 4.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

5.  Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying.

Authors:  Igor A Harsch; Corinna Koebnick; Atingwa M Tasi; Eckhart Georg Hahn; Peter C Konturek
Journal:  Dig Dis Sci       Date:  2008-12-11       Impact factor: 3.199

6.  Beta cell (dys)function in non-diabetic offspring of diabetic patients.

Authors:  M Stadler; G Pacini; J Petrie; A Luger; C Anderwald
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

7.  Leptin, obestatin and apelin levels in patients with obstructive sleep apnoea syndrome.

Authors:  Sabine Zirlik; Tabea Hauck; Florian Siegfried Fuchs; Markus Friedrich Neurath; Peter Christopher Konturek; Igor Alexander Harsch
Journal:  Med Sci Monit       Date:  2011-02-25

8.  Insulin infusion during normoglycemia modulates insulin secretion according to whole-body insulin sensitivity.

Authors:  Christian Anderwald; Andrea Tura; Angela Grassi; Michael Krebs; Julia Szendroedi; Michael Roden; Martin G Bischof; Anton Luger; Giovanni Pacini
Journal:  Diabetes Care       Date:  2011-01-07       Impact factor: 19.112

Review 9.  Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.

Authors:  Elaine Cowan; Kerry J Burch; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2016-05-27       Impact factor: 8.739

10.  Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery.

Authors:  Christian-Heinz Anderwald; Andrea Tura; Miriam Promintzer-Schifferl; Gerhard Prager; Marietta Stadler; Bernhard Ludvik; Harald Esterbauer; Martin Georg Bischof; Anton Luger; Giovanni Pacini; Michael Krebs
Journal:  Diabetes Care       Date:  2012-08-24       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.